Document is current
Any future updates will be listed below
-
Authors
Plumber, Sakina A. https://orcid.org/0000-0003-4822-6765
Tate, Tiffany
Al-Ahmadie, Hikmat https://orcid.org/0000-0002-2938-6627
Chen, Xiao
Choi, Woonyoung https://orcid.org/0000-0003-1088-9539
Basar, Merve
Lu, Chao https://orcid.org/0000-0003-0982-8122
Viny, Aaron https://orcid.org/0000-0001-7039-0110
Batourina, Ekatherina
Li, Jiaqi
Gretarsson, Kristjan https://orcid.org/0000-0002-9616-416X
Alija, Besmira
Molotkov, Andrei
Wiessner, Gregory
Lee, Byron Hing Lung
McKiernan, James
McConkey, David J. https://orcid.org/0000-0003-1971-0638
Dinney, Colin
Czerniak, Bogdan https://orcid.org/0000-0002-8289-9173
Mendelsohn, Cathy Lee https://orcid.org/0000-0002-4026-4073
- License Information
-
More Information
Article History
Received: 28 August 2023
Accepted: 18 July 2024
First Online: 2 August 2024
Competing interests
: C.D. is creator of intellectual property owned by UT/MDACC related to the use of genetic alterations as a predictive biomarker for response to Nadofaragene firadenovec and has stock options and personal compensation from CG Oncology for consulting and advisory services. C.L.M. has performed studies in collaboration with FLARE Therapeutics focused on PPARG inverse agonists in NMIBC. The remaining authors declare no competing interests.
